Physicochemical Properties
| Molecular Formula | C28H18F6N3O2PPT- |
| Molecular Weight | 768.51 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | anti-TNBC agent-6 (compound pt-3) (48 h) is cytotoxic to MDA-MB-231, MCF-7, B16-F10, SK-OV-3, and WI-38 cells[1]. anti-TNBC agent-6 (2 µM; 0, 12, 24, 36, 48 h) induces autophagy by increasing the expression of Beclin-1 and LC3-II in a time-dependent manner in MDA-MB-231 cells[1]. anti-TNBC agent-6 (2 µM; 0, 12, 24, 36, 48 h) induces ferroptosis by decreasing the expression of GPX4 in a time-dependent manner[1]. anti-TNBC agent-6 (1, 2 µM) increases the MDA content in MDA-MB-231 cells in a dose-dependent manner[1]. The anti-TNBC agent-6 (2 µM) enhanced intracellular ROS accumulation and increased the intracellular labile iron pool (LIP)[1]. |
| ln Vivo | anti-TNBC agent-6 (10 mg/kg; ip; on days 0, 3, 6, 9, 12, 15, and 18) showed anti-tumor activity in the MDA-MB-231 xenograft model [1]. |
| Cell Assay |
Cell Cytotoxicity Assay[1] Cell Types: A549, A549/CDDP Tested Concentrations: 0-28 µM Incubation Duration: 48 h Experimental Results: Showed cytotoxic activity with IC50s of 2.84, 4.12 µM for A549, A549/CDDP cells, respectively. Western Blot Analysis[1] Cell Types: MDA-MB-231 Tested Concentrations: 2 µM Incubation Duration: 0, 12, 24, 36, 48 h Experimental Results: Increased the expression of Beclin-1, LC3-II in a time dependent manner. |
| Animal Protocol |
Animal/Disease Models:25 g, 5 weeks, female KM mice (MDA-MB-231 xenograft model)[1] Doses: 10 mg/kg Route of Administration: I.p.; on days 0, 3, 6, 9, 12, 15, and 18 Experimental Results: Significantly inhibited tumor growth compared to the vehicle controls, elicited an inhibition rates of tumor growth (IRT) as high as 65.3%. |
| References |
[1]. Cycloplatinated (II) Complex Based on Isoquinoline Alkaloid Elicits Ferritinophagy-Dependent Ferroptosis in Triple-Negative Breast Cancer Cells. J Med Chem. 2024 Mar 25. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3012 mL | 6.5061 mL | 13.0122 mL | |
| 5 mM | 0.2602 mL | 1.3012 mL | 2.6024 mL | |
| 10 mM | 0.1301 mL | 0.6506 mL | 1.3012 mL |